IKNA vs. VOR, SPRO, XLO, GTHX, IVA, STRO, AVXL, SOPH, MGTX, and SLDB
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Vor Biopharma (VOR), Spero Therapeutics (SPRO), Xilio Therapeutics (XLO), G1 Therapeutics (GTHX), Inventiva (IVA), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), SOPHiA GENETICS (SOPH), MeiraGTx (MGTX), and Solid Biosciences (SLDB). These companies are all part of the "medical" sector.
Vor Biopharma (NYSE:VOR) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Vor Biopharma has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.
Vor Biopharma presently has a consensus price target of $12.50, suggesting a potential upside of 968.38%. Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 72.41%. Given Ikena Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Vor Biopharma is more favorable than Ikena Oncology.
97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 4.7% of Vor Biopharma shares are owned by insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Ikena Oncology's return on equity of 0.00% beat Vor Biopharma's return on equity.
Vor Biopharma received 15 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 65.15% of users gave Vor Biopharma an outperform vote while only 59.57% of users gave Ikena Oncology an outperform vote.
In the previous week, Ikena Oncology had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Ikena Oncology and 0 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.13 beat Ikena Oncology's score of 0.00 indicating that Ikena Oncology is being referred to more favorably in the news media.
Vor Biopharma has higher earnings, but lower revenue than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Vor Biopharma beats Ikena Oncology on 9 of the 15 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
